Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Veliparib |
Synonyms | |
Therapy Description |
Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615, PMID: 31074636, PMID: 32452601). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Veliparib | ABT-888 | PARP Inhibitor (Pan) 31 | Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615, PMID: 31074636, PMID: 32452601). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM over exp | stomach cancer | decreased response | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, high ATM expression was associated with decreased response to Veliparib (ABT-888) in gastric cancer cell lines in culture (PMID: 27638859). | 27638859 |
RAD51C H192_R193delinsGG | ovarian carcinoma | resistant | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C H192_R193delinsGG demonstrated resistance to Veliparib (ABT-888) in culture (PMID: 28588062). | 28588062 |
ATM inact mut | Advanced Solid Tumor | sensitive | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, an ATM-deficient cell line demonstrated increased sensitivity to Veliparib (ABT-888) compared to an ATM-reconstituted cell line, in culture (PMID: 21300883). | 21300883 |
ATM dec exp | stomach cancer | sensitive | Veliparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, knockdown of ATM in a gastric cancer cell line resulted in increased sensitivity to Veliparib (ABT-888) in culture and in xenograft models (PMID: 27638859). | 27638859 |
RAD51C R193W | ovarian carcinoma | resistant | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C R193W demonstrated resistance to Veliparib (ABT-888) in culture (PMID: 28588062). | 28588062 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02470585 | Phase III | Carboplatin Paclitaxel Veliparib | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | USA | POL | NZL | ISR | GBR | ESP | DNK | BRA | AUS | 2 |
NCT01459380 | Phase I | Carboplatin Doxorubicin Veliparib Bevacizumab | Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT00576654 | Phase I | Irinotecan Veliparib | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01489865 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Veliparib | ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer | Unknown status | USA | 0 |
NCT01434316 | Phase I | Dinaciclib + Veliparib Veliparib | Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT01638546 | Phase II | Temozolomide Veliparib | Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | Completed | USA | 0 |
NCT02106546 | Phase III | Veliparib Carboplatin + Paclitaxel | Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | Completed | USA | TUR | SWE | SVK | POL | NZL | NOR | NLD | LVA | LTU | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUT | AUS | 9 |
NCT02985658 | Phase I | Cisplatin Veliparib Vinorelbine | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | No longer available | USA | 0 |
NCT02152982 | Phase II | Veliparib Temozolomide | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Active, not recruiting | USA | 1 |
NCT02305758 | Phase II | Fluorouracil + Irinotecan + Leucovorin Bevacizumab Veliparib | Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | Completed | 0 | |
NCT01326702 | Phase Ib/II | Veliparib Rituximab Bendamustine | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | Completed | USA | 0 |
NCT01281150 | Phase I | Veliparib Paclitaxel Carboplatin | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01618357 | Phase I | Veliparib | Pre-Operative Radiation and Veliparib for Breast Cancer | Completed | USA | 0 |
NCT01853306 | Phase I | Veliparib | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | Completed | 0 | |
NCT02009631 | Phase I | Veliparib | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | Completed | USA | NLD | ESP | 0 |
NCT01264432 | Phase I | Veliparib | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | Completed | USA | CAN | 0 |
NCT01642251 | Phase Ib/II | Cisplatin + Etoposide Veliparib | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02921256 | Phase II | Veliparib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Capecitabine + Veliparib Capecitabine | Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | Completed | USA | 1 |
NCT01514201 | Phase Ib/II | Temozolomide Veliparib | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | Completed | USA | 0 |
NCT01908478 | Phase I | Veliparib Gemcitabine | A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer | Completed | USA | 0 |
NCT02264990 | Phase III | Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers | Completed | USA | TUR | NZL | NLD | ISR | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | AUS | ARG | 5 |
NCT00892736 | Phase I | Veliparib | Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy | Completed | USA | 0 |
NCT01351909 | Phase I | Cyclophosphamide Veliparib | Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02032277 | Phase III | Cyclophosphamide + Doxorubicin Veliparib Carboplatin Carboplatin + Paclitaxel | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | Completed | USA | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 3 |
NCT01017640 | Phase I | Veliparib Mitomycin C + Veliparib | Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors | Completed | USA | 0 |
NCT01585805 | Phase II | Veliparib Cisplatin + Gemcitabine | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Active, not recruiting | USA | ISR | CAN | 0 |
NCT03581292 | Phase II | Temozolomide + Veliparib Veliparib | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT02412371 | Phase II | Veliparib Carboplatin + Paclitaxel | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer | Terminated | USA | 0 |